Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Studies Commence to Ensure Reliability of HIV 1/2 Assay

By LabMedica International staff writers
Posted on 02 May 2013
An HIV 1/2 assay detects antibodies to HIV 1 and 2 in oral fluid, finger-stick whole blood (fingerstick), venous whole blood, serum, or plasma samples. More...


Chembio Diagnostics' (Medford, NY, USA) DPP HIV 1/2 assay provides a simple "reactive/nonreactive" result. In a clinical evaluation of over 3,000 patients across three countries, the diagnostic sensitivity of the DPP HIV 1/2 assay to detect HIV infection ranged from 99.9%–100% for fingerstick specimens and 98.9%–100% for oral fluid specimens. The diagnostic specificity of the DPP HIV 1/2 assay was 100% for fingerstick specimens and 99.9%–100% for oral fluid specimens. The test is intended to be used in the preliminary diagnosis of patients with HIV in point-of-care (POC) settings such as public health and other clinics, hospital emergency rooms and physician offices.

The assay does not use lateral flow or other older flow-through technologies. DPP HIV 1/2 delivers visual results within approximately 15 minutes, is simple to use, requires minimal sample size, has a shelf life of 24 months, and does not require refrigeration. Providing results at the POC eliminates the chance that patients at risk would not return or call back for results, thereby improving prevention efforts of forward transmission.

A convenient swab for collection of oral fluid samples is a feature of DPP HIV 1/2. Sharp distinct test lines are obtained due to the DPP technology. The sample collection system enables each sample to be contained in a convenient, closed collection vial, or Sampletainer, which provides additional sample for repeat testing.

Although the US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved Chembio's new DPP HIV 1/2 Assay multisite assay in December 2012, it requires Clinical Laboratory Improvement Amendments (CLIA) waiver studies to establish the quality standards for laboratory testing. These must ensure the accuracy, reliability, and timeliness of patient tests results regardless of where the tests are performed.

The CLIA clinical study will test samples prospectively collected from approximately 1,000 subjects who are HIV positive and of unknown HIV status. The study is expected to be completed within three to four months. The company anticipates that the FDA's review of the CLIA Waiver Application will be completed during the fourth quarter of 2013.

"We are very pleased to commence the CLIA clinical testing for our DPP HIV 1/2 Assay. It is a key component for Chembio as we finalize our commercial strategy to launch the DPP assay in the US," noted Lawrence Siebert, Chembio's CEO.

Related Links:
Chembio Diagnostics




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.